Bezuclastinib Plus Sunitinib Shows Encouraging Safety and Efficacy Profile in R/R Second-Line GIST
The combination of bezuclastinib and sunitinib had a tolerable safety profile and demonstrated early signals of clinical activity in patients with gastrointestinal stromal tumor.
Memorial Sloan Kettering Cancer Center New York United States Bezuclastinib And Sunitinib Patients With Gastrointestinal Stromal Tumor Peak Trial
Source: onclive.com